Hormonal
Semaglutide treatment in obese patients with type 2 diabetes and severe psoriasis leads to significant improvement in psoriasis severity (PASI) and quality of life, independent of prior biologic therapy failure.
If you have severe psoriasis and type 2 diabetes, ask your doctor about GLP-1 agonists like semaglutide. This case shows it can significantly improve skin lesions and quality of life, even when other treatments failed. It addresses both conditions simultaneously.
Unexpectedly, skin lesions of plaque psoriasis improved. PASI decreased by 19% compared with baseline and quality of life, assessed with the DLQI, markedly ameliorated. After 10 months... PASI were reduced by... 92% compared with the baseline.
Why this rating
This is a single case report (n=1), which provides anecdotal evidence rather than statistical significance from a controlled trial.
Source
Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient
Gabriele Costanzo et al. · Endocrinology Diabetes and Metabolism Case Reports · 2021
DOI 10.1530/edm-21-0007
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →